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ABSTRACT
There are multiple surgical procedures that require vascular or microvascular
anastomosis; some of which include free tissue transfer for soft tissue reconstruction,
vascular grafts and bypass surgeries. The two most common complications with a
procedure involving vascular anastomosis are thrombosis and stenosis. The current
method to prevent anastomotic thrombosis is the use of an anti-coagulant such as heparin.
Heparin has also shown to reduce vascular smooth muscle cell proliferation which is an
initiating factor for intimal hyperplasia and ultimately, stenosis. Another well-known
treatment for stenosis prevention in vascular injuries is the anti-proliferative drug,
paclitaxel. Previously in our 4D lab, we have fabricated and characterized heparinimmobilized electrospun sutures to prevent coagulation after vascular anastomosis. The
objective of this project is to develop an electrospun paclitaxel-eluting suture
incorporating a novel, amphiphilic block copolymer, polyethylenimine-g-poly (D, Llactide-co-glycolide) (PgP), which we have synthesized in our 4D lab, in order to prevent
the proliferation of vascular smooth muscle cells (VSMCs) after anastomosis procedures.
We hypothesize that paclitaxel, a hydrophoboic molecule and anti-proliferative drug, will
bind to the hydrophobic block of our copolymer. Adding this novel copolymer into the
suture is expected to provide sustained and controlled release of paclitaxel in order to
prevent stenosis. We have already successfully immobilized heparin onto the electrospun
fibers and assessed the release kinetics and therapeutic activity in-vitro. In this study, we
incorporated paclitaxel into the electrospun fiber composition and evaluated
physicochemical properties of the paclitaxel loaded electrospun fiber yarns, paclitaxel
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loading efficiency, release kinetics and therapeutic activity in-vitro. In the future, we will
combine both heparin and paclitaxel into the fiber and evaluate the therapeutic effect of
the dual-drug loaded electrospun suture in a rat vein anastomosis model in vivo as well as
optimize the mechanical performance of the fibers to be used as commercial sutures.
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CHAPTER 1 – INTRODUCTION

1.1 Sutures
As a general definition, a suture is a strand of material used to ligate or re-connect
tissue. [1] Sutures are the most widely used medical device in surgical procedures
capturing over a billion-dollar annual market. There are more than 5,000 varieties of
sutures available that range in natural versus synthetic composition, absorbable versus
non-absorbable, monofilament versus multi-filament and size. [1,2] There are pros and
cons to each of these characteristics that a surgeon can use to decide which type is
appropriate for the procedure he or she is to perform. For example, in vascular surgery,
the suture size can range from as large as 3-0 (300-339 um) for use on the aorta to as
small as 7-0 (50-69 µm) for use on renal-visceral arteries based on the scale defined by
the USP (United States Pharmacopeia; Rockville, MD). [3,4]

1.2 Vascular Anastomosis
During nearly every surgical procedure there is some occurrence of broken
vasculature. In most cases, the broken vessels are small and insignificant enough that the
surgeon can cauterize the vessel and allow self-healing. However, when major blood
vessels are broken, vascular anastomosis, or ligation, is required to restore the patency of
the vessel. Vascular anastomosis uses surgical sutures to reconnect broken blood vessels
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either end-to-end, end-to-side or side-to-side as
seen in Figure 1. Although primarily used by
vascular surgeons, this technique is also applied
by a variety of surgical specialties such as
cardiovascular, plastic and reconstructive,
otolaryngology, and orthopaedic. [5,6] There
are many procedures that may require a version
of vascular anastomosis, some of which
include: free-tissue transfer, vascular graft
implantation, and bypass surgery. [5,7] The
vessels that require this reconstruction can
Figure 1. Visual representation of the variations in
anastomosis techniques.

range in size from the large root of the aorta

[http://medical-dictionary.thefreedictionary.com/anastomosis]

to very small vessels such as digital arteries
which require microvascular anastomosis. [3] Some of the complications of vascular
anastomosis include anastomotic thrombosis and stenosis caused by intimal hyperplasia
which are consequences of the inherent injury to the vascular wall.

1.3 Vascular Anastomosis Complications
1.3.1 Anastomotic Thrombosis
When vasculature is broken and subsequently reconnected with sutures by
anastomosis, an inflammatory response occurs triggering the coagulation cascade.
Although coagulation is the body’s natural response to injury, it can cause serious
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complications under certain
circumstances. [6] The coagulation
cascade leads to the development of a
thrombus or blood clot within the vessel
as seen in Figure 2. This clot can cause
the vessel to become occluded which
typically occurs within 48 hours in
Figure 2. Illustration of a thrombus formation
within a blood vessel
[https://www.youtube.com/watch?v=eK5MeJuUQbs]

approximately 80% of cases resulting in
thrombotic occlusion. [8] A thrombus

can also lead to the formation of an emboli, or mobile clot, which can cause serious comorbidities such as stroke. Anastomotic thrombosis is also known to be the leading cause
of graft failure in free-tissue transfer procedures. Approximately 4 percent of free flaps
and 10 to 30 percent of digital replantations experience failure due to thrombosis. [9,10]
It is imperative that coagulation be prevented so that thrombosis does not occur at the site
of injury during vascular anastomosis procedures.
1.3.2 Intimal Hyperplasia and Vascular Stenosis
Similar to anastomotic thrombosis, vascular stenosis - or narrowing of the vessel,
occurs due to the onset of injury to the vascular wall. This damage leads to a chronic
inflammatory response causing platelet aggregation and an infiltration of leukocytes. A
biochemical imbalance then occurs and transforms the vascular smooth muscle cells
(VSMCs) from the native contractile state to a myoproliferative state. The VSMCs begin

3

to proliferate in the media of the
vessel wall. Eventually, the VSMC
proliferation migrates into the intima
of the vessel thickening the arterial
wall. [11]
This thickening progression
of the tunica intima is called intimal

Figure 3. Histology of vessel wall borrowed from MGH
Center for Systems Biology Research Laboratories
[https://csb.mgh.harvard.edu/stone/research_projects]

hyperplasia and it occurs throughout the first 18-months post-injury and eventually
follows the same pathogenesis as atherosclerosis as seen in Figure 3. [3] Ultimately,
intimal hyperplasia causes arterial stenosis, or narrowing of the vessel opening,
restricting blood flow through the artery. Since approximately 50% of vein grafts and
30% of all arterial bypass grafts fail due to vascular stenosis, it is vital that proliferation
of VSMCs be inhibited to prevent intimal hyperplasia and stenosis following a vascular
anastomosis procedure. [11]
1.4 Anti-Coagulant Drugs
Currently in vascular surgery, the gold standard for preventing thrombosis and
improving vessel patency is the use of the anticoagulant drugs heparin, aspirin, and
dextran. Most commonly used is the systemic delivery of heparin. Heparin is a highly
sulfated glycosaminoglycan and is known to have an extremely high negative charge
density. Heparin works by binding to and activating antithrombin III which then prevents
thrombin from activating factors V, VIII and Xa in the coagulation cascade. This
disruption ultimately prevents the formation of a thrombus. However, there are some
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negative side-effects to the current systemic use of heparin such as uncontrolled bleeding,
easy bruising and heparin-induced thrombocytopenia (HIT) putting the patient at risk of
hemorrhage. [6]
1.5 Anti-Proliferative Drugs
More commonly known as a chemotherapy agent, paclitaxel (or Taxol), is also
widely used as to prevent proliferation of VSMCs in vascular procedures such as balloon
angioplasty or stent implantation. Paclitaxel is the structurally most complex member of
the taxane family possessing a unique tetracyclic 17-carbon skeleton which can be seen
in Figure 5. [12] Paclitaxel works by stabilizing polymerized microtubules and enhancing
microtubule assembly which inhibits cell replication in the G0/G1 and G2/M phases of the
cell cycle leading to cell death or apoptosis. [13]
In addition to its anticoagulant effects, heparin has also known to inhibit the
proliferation of VSMCs. Several theories for this have been studied, including the
suppression of early VSMC genes, inhibition of production of matrix-degrading proteases
that allow cell migration and proliferation, and the inhibition of mitogen-activated protein
kinase. [11]
1.6 Electrospinning
1.6.1 General Electrospinning
Over the last decade, a new fabrication technique called electrospinning has
become increasingly popular in the biomedical field. The general appeal of this process
stems from its low cost, easily customizable parameters, and simple one-step production
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which has led to the exploration of its use in a variety of biomedical applications
including surgical sutures. [2]
Electrospinning uses an electrical field to draw a thin jet from a polymer-solutionloaded capillary. Although setup configurations may vary depending on the application,
the typical setup consists of a high voltage power source, a spinneret (i.e. syringe and
needle), and a grounded collector. A polymer dissolved in a volatile solvent is loaded into
a syringe with a blunt tip needle. When a voltage source is applied to the needle tip as the
syringe slowly pumps out the polymer solution, the droplet is stretched toward the
grounded collector due to an electrostatic repulsion that is counteracted by the surface
tension as the solvent evaporates. At a critical point, a ‘Taylor cone’ forms causing a thin
stream to erupt from the stretched droplet creating a nanofiber jet that dries in flight on its
way to the grounded collector. [14,15]
1.6.2 Electrospinning for Drug Delivery
Electrospinning provides for a relatively simple and adaptable production of
nanofibers which are appealing for drug delivery applications due to a high surface area
to volume ratio, the potential for surface modification, flexibility in material selection,
and a variety of drug loading methods. [16,17] The high surface area to volume ratio is
particularly appealing for drug-delivery applications as it allows for a high drug-loading
capacity. Additionally, the flexibility in material selection allows for the use of both
biodegradable or non-degradable materials which can have a significant impact on the
desired drug-release pattern as well as the mechanical integrity of the material over time.
[15]
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There are several methods currently used for incorporating a drug into the
electrospinning process. The first method is simple drug loading where the drug is added
to the polymer solution before fabrication of the nanofibers which usually exhibits a high
loading efficiency. Another method is post-fabrication surface modification where the
drug is either coated or immobilized onto the surface of the electrospun material. This
method is ideal for sensitive drugs that may involve proteins or DNA that cannot be
subject to the volatile organic solvent or the high voltage applied during the
electrospinning process. Co-axial and layer-by-layer techniques are also widely appealing
for incorporating drugs with specific control over the release kinetics. Commonly in coaxial electrospinning, a core of drug loaded polymer is surrounded by a sheath layer
which is specifically designed to control the drug-release based on diffusion or
degradation rates. [18]
1.7 Current Approaches
The use of electrospun nanofibers as a drug delivery system has become very
popular among researchers – particularly as surgical sutures. In 2010 Hu et al. was able to
fabricate electrospun braided antibiotic-loaded sutures that displayed antibacterial activity
for up to 10 days with a low initial burst release followed by a sustained release profile
which is ideal for prevention of infection as an initially high dose of antibiotics will help
to kill any bacteria present in the wound. [19]
A study done by Weldon et. al in 2012 successfully electrospun PLGA with the
drug bupivacaine hydrochloride, a common local anesthetic, to create a local anestheticeluting biodegradable suture. A release study showed that 100% of the drug was released
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after 12 days and the in-vivo study demonstrated that analgesia was achieved one day
after surgery and was sustained for one week in 90% of the animals. These results
showed promise for the use of local anesthetics in sutures to prevent the use of postoperative opioid analgesics. [20]
More recently, Padmakumar et. al electrospun drug-eluting sutures using the coresheath method in 2016. The drugs aceclofenac and insulin were incorporated into the
poly-lactic-co-glycolic acid (PLGA) sheath which surrounded a poly-L-lactic acid
(PLLA) core to demonstrate that both chemically and biologically active drugs can be
electrospun into the suture. Their reasoning for using this core-sheath method was for the
ability to incorporate the drugs into the suture for better loading efficiency and release
kinetics compared to drug-coated sutures, but to maintain the strength with a
mechanically robust core. Studies showed that sutures incorporated with aceclofenac and
insulin allowed 15% and 4% loading and achieved release for ten and seven days
respectively and both types of drug loaded sutures displayed effective therapeutic
activity. [21]
When it comes to mitigating thrombosis and stenosis following vascular injury,
there are many approaches being explored. One of the most recent successes was the
creation of drug-eluting stents which was first approved by the FDA in 2003. Most
commonly, the drugs used in these stents are either sirolimus or paclitaxel which are both
intended to combat post-stent restenosis caused by the excessive proliferation of VSMCs
following endothelial injury, as discussed previously. [22]

8

In 2006, Luong-Van et. al. explored the idea loading heparin on the surface of
electrospun poly(ε-caprolactone) mats in order to achieve sustained localized release of
heparin at the site of grafted blood vessels to prevent VSMC proliferation. The group was
able to homogenously load heparin throughout the electrospun mat and achieved
approximately 50% release after 14 days. The electrospun mats were also successful at
inhibiting the proliferation of VSMCs in-vitro. [11]
These studies demonstrate a great potential for the use of electrospun drug-eluting
sutures to locally address a variety of conditions such as surgical site infections, local
anesthesia, and inflammation. Currently, Ethicon is the only company to successfully
market a drug-loaded suture in the US. However, these sutures are extruded in a process
similar to synthetic textiles and then coated with an antimicrobial agent. [2] This
relatively new and untouched market continues to inspire researchers to develop drugeluting sutures to locally deliver therapeutics, and electrospinning shows great promise as
a manufacturing method.
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CHAPTER 2 – RESEARCH OBJECTIVE
2.1 Research Rationale
The overall goal of this research project is to develop a combination drug-eluting
suture that will provide both anticoagulant and anti-proliferative effects at the local injury
site of a vascular anastomosis procedure in order to combat anastomotic thrombosis and
stenosis. The suture will be fabricated using electrospinning techniques and will
incorporate the anticoagulant heparin and the anti-proliferative drug paclitaxel. The
polymeric solution used for
electrospinning will be composed of
three polymers: poly(lactide-coglycolic acid) or PLGA,
poly(ethylene oxide) or PEO, and the

Figure 4. PgP chemical structure

novel polyethylenimine-g-poly(D, Llactide-co-glycolide) or PgP. The polymer PgP is a cationic amphiphilic block copolymer
and its chemical structure can be seen in Figure 4.
It is hypothesized that heparin, a negatively charged molecule, will bind to the
positively charged polyethylenimine or PEI block of the PgP copolymer. It is also
anticipated that paclitaxel, a hydrophobic molecule, will bind to the hydrophobic block of
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the PgP copolymer. A schematic representation of these interactions can be seen in
Figure 5.

Figure 5. Heparin molecules are electrostatically bound to the surface of the suture by the
positive PEI block of the PgP copolymer and paclitaxel molecules are contained within the
suture and interact with the negative, hydrophobic block of the PgP copolymer.

Therefore, the incorporation of the novel PgP copolymer into the suture is expected to
improve loading efficiency and provide sustained and controlled release of both heparin
and paclitaxel in order to prevent thrombosis and stenosis.
Previously in the 4D lab, an electrospun fiber containing the PgP polymer was
successfully fabricated and characterized. The PgP incorporated fibers were then
immobilized with heparin and the loading efficiency and release kinetics were evaluated
in comparison to non-PgP fibers in order to confirm the heparin-PEI electrostatic
interaction. The yarns containing a higher presence of PEI showed increased loading
efficiency as well as a slower, more sustained release of heparin over time. Therapeutic
activity of the immobilized heparin was then investigated with an activated partial
thromboplastin time (APPT) test. The test showed an increased clotting time for the

11

samples containing fibers loaded with more heparin. These positive results were the first
step in preventing anastomotic thrombosis.
2.2 Project Aims
In order to reach the overall project goal, both anastomotic thrombosis and
stenosis must be addressed. By incorporating the anti-proliferative drug paclitaxel into
the electrospun fibers, VSMC proliferation can be inhibited which will prevent intimal
hyperplasia from occurring in the vessel wall. The next step of this project is to
investigate the potential for paclitaxel-loaded electrospun fibers for vascular suture
applications. This objective will be met by the following aims:
Aim 1: Fabricate and characterize the mechanical properties of paclitaxel-loaded
electrospun fibers.
Aim 2: Evaluate the loading efficiency and release kinetics of paclitaxel from the
electrospun fibers.
Aim 3: Evaluate the therapeutic activity of paclitaxel released from the electrospun
fibers.
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CHAPTER 3 – MATERIALS & METHODS
3.1 Materials
Poly (lactic-co-glycolic acid) (PLGA) (50:50, 50kDa;50:50, 100kDa) was purchased
from Durect Corporation (Cupertino, CA). Poly(ethylene oxide) (PEO) (1000kDa),
anhydrous dimethylformamide (DMF), N-N-Dimethylacetamide (DMAc), Nhydroxysuccidimide (NHS), dicyclocarbodiimide (DCC), branched polyethylenimine (bPEI) (25kDa) and Thiazolyl Blue Tetrazolium Bromide (MTT) were obtained from
Sigma-Aldrich (St. Louis, MO). Dimethylsulfoxide (DMSO) and Acetonitrile (ACN)
were obtained from Thermo Fisher Scientific (Waltham, MA). Paclitaxel was purchased
from LC Labs (Woburn, MA).
3.2 Synthesis of (polyethylenimine-g-poly (D,L-lactide-co-glycolide)) PgP
PgP was synthesized using poly(lactic-co-clycolic acid) (PLGA) and branched
polyethylenimine (PEI) at a 10:1 molar ratio of PLGA:PEI. Dimethylformamide (DMF)
was dried overnight using a molecular sieve. To activate the carboxylic end group of
PLGA, N-hydroxysuccidimide (NHS) and dicyclocarbodiimide (DCC) were added to the
PLGA solution and stirred at room temperature for 2 hours. A glass funnel with a fine
pore size was used to filter the resulting precipitate, dicyclohexyl urea (DCU). The
dissolved PEI solution was added dropwise to the activated PLGA filtrate solution for 30
minutes and then stirred at room temperature for 24 hours to complete the reaction.
The reaction solution was then transferred to dialysis membranes (MWCO=50,000)
in deionized water for a total of 2 days. The water was removed and replaced at 2, 4, 6
and 24-hour time points throughout the dialysis. The product was then centrifuged at
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5,000 rpm for 10 minutes. The precipitate and supernatant were separated and freezedried for analysis and use. The final structure of PgP was verified by dissolving 10 mg of
product in 1 mL of deuterated DMSO (DMSO-d6) and using 1H-NMR on a Bruker
300MHz.

Figure 6. Synthesis of PLGA-g-PEI
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3.3 Electrospinning
3.3.1 General Electrospinning Setup
The electrospinning setup used for
this project was developed by Dr.
Konstantin Kornev’s group and is
maintained by Dr. Guzeliya
Korneva. [23] The setup shown in
Figure 7 consists of an automated
syringe pump sitting on an
adjustable platform (c), a 10mL
Teflon coated syringe (a) coupled

Figure 7. Illustration of electrospinning setup

with a blunt tip needle (b) from which the polymer jet emerges, a high voltage power
source (d) that is connected to the syringe needle by an alligator clip and is also grounded
to the rotating mandrel collector (f). Although not shown in Figure 7, the syringe and part
of the needle is wrapped with a heat sleeve set to 60⁰C in order to prevent the polymeric
solution from solidifying during the electrospinning process.
3.3.2 Polymer Solution Preparation
There were four polymeric solutions used for electrospinning during this study
which are described in Table 1. The electrospinning solutions were generally prepared by
adding the required amount of PLGA (50:50,100kDa) to dimethylacetamide (DMAc) and
stirring at room temperature until fully dissolved. PEO (1000kDa) was then added to the
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solution along with heat (~60⁰C) until fully dissolved. When necessary, PgP and/or
paclitaxel were dissolved separately in DMAc and then added to the fully dissolved and
warmed PLGA/PEO solution.
Table 1. Polymeric solution compositions dissolved in 3 mL DMAc used for electrospinning

3.3.3 Electrospinning Process
Once the desired polymer solution had fully dissolved, it was transferred to a prewarmed 10mL Teflon-wrapped syringe with a blunt tip needle. The polymer filled
syringe was then placed in the syringe pump and wrapped in a heat sleeve set to 60⁰C.
The positive voltage source was connected to the needle by an alligator clip and the
negative voltage source was connected to the base of the custom made spinning mandrel
to ground the collector. During the spinning process, the nanofibers were uniformly
collected around the mandrel as seen in Figure 8(B) for one hour. After 30 minutes, the
mandrel direction was reversed. The room temperature, humidity, gap distance, applied
voltage, flow rate, spin time and twist time were recorded for each spin. To control the
humidity, when necessary, the electrospinning setup was done within a custom made
chamber connected to a humidifier as seen in Figure 8(A).
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Figure 8. Images of the electrospinning setup and rotating mandrel used in this study and
step-by-step collection of electrospun nanofibers from the mandrel followed by the
twisting into uniform fibers using the custom twisting device.
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Table 2. List of parameters maintained during the electrospinning process.

3.3.4 Collection of Nanofibers & Formation of Twisted Fiber Suture
The aligned nanofibers were then collected using a custom made device which
consisted of two round brushes which could be adjusted to the same inner distance
between the mandrel arms Figure 9.
The brushes were manually rolled from
the bottom of the mandrel to the top
collecting the fibers into a cylindrical
web of nanofibers as seen in Figure
8(C-E). The device was then connected
to a powered motor that twisted the

Figure 9. Custom nanofiber collecting and
twisting device

brushes in opposite directions at the same speed, forming a uniformly twisted fiber after
30-60 seconds Figure 8(F-G). The fiber was then cut at each end and stored in a petri
dish. This process was repeated for each side of the mandrel resulting in four fibers each
batch. The fibers were placed in a desiccator for at least 24 hours before testing.
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3.4 Fiber Characterization
3.4.1 Fiber Imaging
After fabrication, phase contrast microscopy (Axiovert S100) was used to both
visualize the fibers produced and measure the diameters. Images were taken at 10x
magnification using ProgRes Capture Pro 2.10.0.1 at 15ms exposure. The diameter of the
fiber was measured using iSolution software version 10.1 calibrated for micrometers. In
order to obtain an accurate measurement, the diameter was measured at three different
locations along the length of the fiber and the measurements were averaged.
3.4.2 Mechanical Tensile Testing
In order to determine the
mechanical tensile properties of
the electrospun fibers, an Instron
5944 Material Testing Frame
was used to perform tensile
tests. Before testing, the fiber
was cut into 5 cm segments and
clamped into the grips on the
machine with an approximate
gauge length of 4 cm. Once the
fiber was secured, the upper
clamp was manually raised until
the fiber was taught. This

Figure 10. Instron during testing of electrospun fiber.
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distance was measured and recorded in the software along with the fiber’s average
diameter measured previously. Before the test was run, the load and the gauge distance
was zeroed. The test was run using a 50N load cell under uniaxial tension at a rate of 5.0
mm/min. Tests were run until the fiber failed.
The Bluehill 2 software provided by Instron output the raw data, a stress-strain
curve, as well as calculations of Young’s Modulus, tensile stress at yield, tensile strain at
yield, and load at yield for each sample tested. Based on the user’s discretion, a stressstrain curve was created in Microsoft Excel from the raw data provided in order to obtain
more accurate calculations of tensile properties such as Young’s Modulus. This was done
by manually determining the slope of the linear plastic region of the stress-strain curve
using Excel’s slope function.
3.5 Paclitaxel Loading Quantification
To determine the amount of paclitaxel that was successfully loaded into the
electrospun fibers containing paclitaxel (PP+Pac and PPP3.7+Pac), small amounts of
fibers of known mass were allowed to fully dissolve in DMSO for at least 4 hours. The
resulting DMSO solution was filtered using 0.2 µm pore size filters and tested using High
Performance Liquid Chromatography (HPLC) using a Waters 1525 Binary HPLC Pump
and 2707 Autosampler. The HPLC method used to detect paclitaxel was adapted from
S.C Kim et al. [12] A Waters Symmetry C18 column was used with a mobile phase of
50:50 deionized water and HPLC grade acetonitrile with a gradient flow rate of 1.0
mL/min. PDA (photodiode array) detection was performed at 227nm to obtain the
absorbance peak for the paclitaxel. The injection volume was 50 µL which ran for 32
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minutes, and the retention time for the paclitaxel peak was 19.3 minutes. In order to
quantify the resulting peaks, they were first integrated and the areas were compared to the
integrated peaks of the prepared standards of known paclitaxel concentrations in DMSO
using a standard curve. The average sample concentration was converted to µg of
paclitaxel per milligram of fiber based on the mass of the fiber dissolved.
In order to determine the efficiency of the paclitaxel loading into the electrospun
fibers, the amount of drug loaded into the fiber must be compared to the total drug
originally dissolved in the electrospinning solution. The ratio of drug to fiber determined
by the loading study was divided by the ratio of total drug dissolved to total polymer
dissolved in the electrospinning solution which provided the drug loading efficiency.
3.6 Paclitaxel Release Study
Once the amount of paclitaxel loaded into the PP+Pac and PPP3.7+Pac fibers was
known, the release kinetics of the drug from the electrospun fibers were investigated.
Approximately 5 mg of each fiber type was added to 1 mL of phosphate buffered saline
(PBS) and incubated at 37⁰C to simulate physiologic conditions. At 0, 1 hour, 2 hours, 4
hours, 8 hours, 24 hours and every day for 7 days, the PBS solution was removed from
the fibers and placed in a -80⁰C freezer. Fresh PBS was then added back onto the fiber
and returned to the incubator until the next time point.
Before testing, the samples were removed from the freezer and lyophilized for 48
hours. Once freeze-dried, the samples were centrifuged, re-suspended in 250 µL of
DMSO and centrifuged again at 10,000 rpm for 5 minutes. The supernatant was then
removed and filtered using a 0.2 µm filter in order to test the sample with HPLC. The
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same HPLC methods discussed previously were used to determine the amount of
paclitaxel released. PPP3.7 fibers not containing paclitaxel and PBS alone were used as
controls to ensure that no peak would be detected without the presence of paclitaxel.
Each type of fiber was tested in triplicate.
3.7 VSMC Proliferation Inhibition Assay
To ensure that the activity of the paclitaxel loaded in the electrospun fibers was not
compromised during the electrospinning process, a proliferation inhibition assay was
performed on primary rat vascular smooth muscle cells (VSMCs) adapted from LuongVan et. al. [11] The cultured VSMCs were plated at approximately 1x104 cells/cm2 in
complete DMEM media containing 10% fetal bovine serum (FBS) and 1%
penicillin/streptomyosin (pen/strep) and allowed to attach for 24 hours. The VSMCs were
then serum starved in DMEM media containing 1% FBS and 1% pen/strep for 72 hours.
Based on the results from the loading study fibers were weighed out to contain
approximately 2 µg of paclitaxel. The pre-weighed fibers were sterilized by rinsing two
times in sterile deionized water and were added to the wells with the cells along with
complete DMEM containing 10% FBS 1% pen/strep. Untreated cells were used as a
control. Cells treated with PPP3.7 fibers without paclitaxel and cells treated with free
paclitaxel dissolved in DMSO added at a concentration of 0.3 µg/mL based on the results
from the release study were used for comparison.
After three days, cell proliferation inhibition was tested using a MTT assay. The
media and fibers from each well were removed and then 12.5 µL of 2 mg/mL Thiazolyl
Blue Tetrazolium Bromide (MTT) in PBS reagent along with 200 µL of media were
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added into each well. The cells were then incubated for 4 hours to allow the conversion
of MTT into formazan crystals by the metabolically live cells. The media with MTT
reagent was then removed and replaced with 100 µL DMSO to dissolve the crystals. The
plate was read by a Biotek Synergy4 multi-detection plate reader to determine the
absorbance of each well. The absorbance values were then compared to the averages of
the positive and negative controls to determine the percent of growth inhibition on the
VSMCs.
3.8 Data and Statistical Analysis
The data presented for mechanical testing, drug loading, loading efficiency, drug
release and therapeutic activity are given as means ± standard error of the mean (SEM).
All statistical analysis was assessed with one-way ANOVA followed by a Turkey posttest using GraphPad Prism 7.0.
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CHAPTER 4 – RESULTS & DISSCUSION
4.1 Synthesis and Characterization of PgP Polymerization
PgP 3.7 was successfully synthesized using the molar ratios of PLGA and bPEI
(10:1). The structure of PgP and the grafting ratio of PLGA to bPEI were verified by 1HNMR (DMSO-d6) (δ = 1.47 (3H, PLGA –CH3), δ = 3.2–3.7 (PEI backbone –CH2CH2–),
δ = 4.9 (2H, PLGA –CH2), δ = 5.2 (1H, PLGA –CH)). The ratio of the integrals of the
PEI backbone (δ = 3.4) to the methine of PLGA (δ = 5.2) demonstrated that
approximately 3.7 PLGA molecules were grafted to 1 bPEI molecule and molecular
weight of PgP1 was about 210,000 Figure 11.

Figure 11. NMR spectra of PgP3.7 in DMSO
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4.2 Electrospinning
The polymers selected for this application were chosen based on a number of
factors. The polymer PLGA is not only FDA approved for use in commercially available
sutures, but it is also biodegradable and soluble in multiple solvents commonly used for
electrospinning. [17,24,25] A high molecular weight PLGA with an inherent viscosity of
0.95-1.20 dL/g was chosen for several reasons. Using a higher molecular weight polymer
will not only benefit the mechanical strength of the fibers, but is also shown to slow
degradation rates compared to polymers with lower molecular weights. [26] Decreasing
degradation rate is extremely beneficial when trying to achieve slow and sustained drug
release. [27] An increased solution viscosity is also shown to improve electrospin-ability
and produce nanofibers of more uniform diameters. [17] A small amount of high
molecular weight Poly(ethylene oxide) (PEO) was also added to the solution help
improve the spin-ability of the PLGA in the presence of PgP3.7. [28]
The solvent selection for an electrospinning application is very important to the
spin-ability of the solution. The solvent DMAc was chosen for this application for
multiple reasons. PLGA was able to dissolve in the solvent at room temperature in a
relatively short period of time (1-2 hours) and in an even shorter period of time when
heated at ~60⁰C (10-20 min). DMAc was also able to dissolve PgP3.7 which does not
readily dissolve in most solvents. However, PEO would not dissolve in the solvent at
room temperature, but was able to dissolve when heated to ~60⁰C. Once PEO was
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dissolved, the solution would solidify when cooled to room temperature, so constant heat
was applied to the solution using a heat sleeve over the syringe during electrospinning.
As stated previously, there are a variety of parameters than can affect the quality
of electrospinning such as humidity, temperature, flow rate, applied voltage and distance
from needle to collector. The parameters listed in Table 2 were maintained as consistently
as possible for each batch of fibers produced. The most challenging parameter to
maintain was the relative humidity. Particularly in the winter when the humidity dropped
below 50% (sometimes as low as 20%), it was nearly impossible to produce a consistent
polymer stream. In these circumstances, the insulated box was connected to a humidifier
in order to attain a humidity above 50%.
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4.3 Electrospun-Fiber Characterization
4.3.1 Surface Morphology of Paclitaxel-Loaded Electrospun Fibers

Figure 12. Phase contrast microscopy images of PPP3.7 and
PPP3.7+Pac fibers at 10x objective magnification.

The phase contrast microscopy images in Figure 12 show the general appearance
of the electrospun fibers produced with and without paclitaxel. Both fiber types seem to
have similar diameters and shape as well as a considerable amount of stray fibers
extending from the surface. This is likely explained by the electrostatic nature of the
individual nanofibers caused by an imbalance of positive and negative charges. During
the collecting and twisting process, the nanofibers are easily attracted to any approaching
object due to electrostatic interactions causing some to stray from the alignment along the
length of the mandrel. Further investigation into the surface morphology using more
powerful imaging technology such as scanning electron microscopy (SEM) imaging

27

should be pursued in future studies as well as investigating potential solutions to reduce
the stray nanofibers during the fiber fabrication process.
The diameters of each fiber were also determined and are listed in Table 3. These
diameters fall between USP absorbable suture sizes 4-0 (150-199 µm) and 3-0 (200-249
µm) which are both commonly used for large vessels such as the aorta, however would
be on the large side for anastomosis of smaller vessels which usually require sizes 5-0
(100-149 µm) to 7-0 (50-69 µm). [4] There was often slight variation in the diameter of
fibers within and between batches. This is likely due to minor deviations in
electrospinning parameters such as humidity, applied voltage, and spin time.
Table 3. Mechanical properties of each type of electrospun fiber. Data given as Mean ± SEM.

4.3.2 Mechanical Properties of Paclitaxel-Loaded Electrospun Fibers
When determining the mechanical properties of surgical sutures, there are two
main tensile tests used: straight-pull and knot-pull. Based on testing performed in similar
literature, straight-pull tensile testing was used for this study since it provides a better
understanding of the overall mechanical behavior. The mechanical properties of each
type of fiber are provided in Table 3 which are also illustrated in graphical form in Figure
13 with statistical analysis presented. Fibers containing PgP3.7 seemed to perform better
than those without in most of the mechanical property categories. As seen in Figure
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13(A,B,D) the tensile strength, peak load and modulus of PPP3.7 fibers and PPP3.7 fibers
containing paclitaxel (PPP3.7+Pac) were significantly different from non-PgP fibers with
p-values less than 0.0001 and at least less than 0.05, respectively. This evidence suggests
that the incorporation of PgP3.7 into the electrospun fibers has a significant positive
impact on the mechanical properties. The tensile strength, peak load and modulus of the
PPP3.7 fibers was also significantly different from the paclitaxel containing fiber of the
same composition (PPP3.7+Pac) with a p-value less than 0.0001. According to a study
done by C. Johnson et. al in 2016, the incorporation of a drug into electrospun fibers has
a significant effect on the physical characteristics of the fibers. This is suggested to be
due to smaller diameter nanofiber production and lower alignment of nanofibers collected
which could explain why fibers containing paclitaxel did not perform as well
mechanically as fibers of the same composition without the drug incorporation. [14] With
further investigation into the surface morphology of the electrospun fibers using more
advanced imaging methods as suggested previously, it could be determined whether or
not the diameter and alignment of the nanofibers within the paclitaxel containing fibers
differs from the fibers not containing the drug to test this hypothesis.
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Figure 13. Tensile properties of electrospun fibers: (A) Tensile strengths; ****=p<0.0001
compared to PP and PP+Pac, ####=p<0.0001 compared to PPP3.7+Pac (B) Peak load values;
****=p<0.0001 and **=p<0.01 both compared to PP and PP+Pac, ####=p<0.0001 compared
to PPP3.7+Pac (C) Percent elongation values; **=p<0.01 and *=p<0.05 both compared to
PP+Pac (D) Young’s Modulus values; ****=p<0.0001 and **=p<0.01 both compared to PP
and PP+Pac, ####=p<0.0001 compared to PPP3.7+Pac. Mean ± SEM.
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It must also be noted that even the PPP3.7 fibers with an average tensile strength
of approximately 23 MPa, elastic modulus of nearly 900 MPa and peak load of 0.45 N
are much weaker than both comparable commercially available sutures and knot-pull
strengths required by the USP for sutures of similar size. Ethicon’s Vicryl® sutures, also
composed of PLGA, have minimum tensile strength and elastic modulus requirements of
410 MPa and 1,400 MPa, respectively. [29] The USP required knot-pull strength for size
4-0 synthetic sutures is 9.32 N, more than twenty times greater than PPP3.7 electrospun
fibers.
Isolated stress-strain curves for each fiber type were compiled and over-laid in
Figure 14 to demonstrate that although some of the mechanical properties vary between
each fiber type, the trend in elastic and plastic regions is similar indicating the ductility of
the fibers remains consistent.

Figure 14. Stress-strain curves of each type of electrospun fiber
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4.4 Paclitaxel Loading of Electrospun Fibers
Since paclitaxel has shown to be therapeutically active at concentrations as low as
0.05 µg/mL, a sensitive detection method such as HPLC (high performance liquid
chromatography) must be used for pharmacokinetic analysis. [12] Before testing the
samples, a series of standard curves with known concentrations of paclitaxel dissolved in
DMSO ranging from 0.001 µg/mL to 10 µg/mL were run through the HPLC column to
determine the detection limit. Below a concentration of 0.25 µg/mL, the PDA
(photodiode array) was unable to detect an absorbance peak.
During the electrospinning solution preparation, approximately 2 mg of paclitaxel
was dissolved in either 15% PLGA [450 mg] 1% PEO [30 mg] (PP+Pac) or 15% PLGA
[450 mg] 1% PEO [30 mg] 0.067% PgP3.7 [2 mg] (PPP3.7+Pac) in 3 mL DMAc as
outlined in Table 1. Therefore, there is theoretically 1 mg of paclitaxel for every 240 mg
of polymer (approx. 4.17 µg paclitaxel per mg polymer). Since the detection limit of
paclitaxel in DMSO was approximately 0.25 µg/mL, a relatively small mass of fiber
could be dissolved in DMSO to prepare an expected concentration of 2 µg/mL. The
results for the loading evaluations are given in Table 4 and are also presented graphically
in Figure 15 with statistical analysis.
Table 4. Loading results of electrospun fibers containing paclitaxel. Mean ± SEM.
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Figure 15. Drug loading evaluations: (A) Amount of paclitaxel loaded per mg of electrospun
fiber. (B) Percent of paclitaxel loaded into the electrospun fiber compared to the total amount of
paclitaxel added to the electrospinning solution. *=p<0.05 compared to PP+Pac. Data is
presented as Mean ± SEM.
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According to these results, electrospun fibers containing PgP3.7 were statistically
able to load more paclitaxel per milligram of fiber and were also more efficient at loading
paclitaxel compared to fibers without. These results support our hypothesis that the
hydrophobic region of PgP3.7 will bind to the hydrophobic drug paclitaxel, increasing
loading efficiency of the electrospun fiber.
4.5 Paclitaxel Release Kinetics
The release profile of paclitaxel from the electrospun yarns over 24 hours and 7 days
are provided in Figure 16. During the first 24 hours, both fibers demonstrated slow and
sustained release kinetics with only around 7.5% released from PP+Pac and 10.6%
released from PPP3.7+Pac. After 7 days, the release pattern is still slow and sustained
with less than 15% and 20% of paclitaxel released from PP+Pac and PPP3.7+Pac
respectively. Although the highest rate of VSMC proliferation occurs within the first 7
days, it is shown to continue for as long as 14-28 days depending on the severity of
injury. [11] If this release pattern were to continue at this rate, small concentrations of
paclitaxel could be released from the fiber for more than 30 days. It is noted that there
seems to be a peak in release between 4 and 5 days, this is possibly due to slight
variations in collection time from day-to-day and small sample population. With the
addition of more data points this will likely smooth out.
Electrospun fibers containing PgP3.7 released slightly more paclitaxel than those
without which is expected due to the higher loading capacity of PgP3.7 containing fibers
discussed previously. Since more palclitaxel was loaded into these fibers, they would
elute more drug at a given time point due to the concentration gradients.
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Figure 16. Drug release profiles of PPP3.7, PP+Pac and PPP3.7+Pac electrospun fibers over
(A) 24 hours and (B) 7 days. *=p<0.05 compared to PP+Pac using 2-tailed t-test. Data
presented as Mean ± SEM.
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4.6 Therapeutic Activity of Paclitaxel-Loaded Fibers
In order to prevent intimal hyperplasia from occurring and causing stenosis of the
vessel following anastomosis, proliferation of VSMCs must be inhibited. After treating
the VSMCs for 3 days with PPP3.7 fibers, PPP3.7+Pac fibers and paclitaxel alone, the
percent growth inhibition was determined and the results are shown in Figure 17. All
three treatments were significantly different compared to untreated cells. The
PPP3.7+Pac fibers, which inhibited approximately 40% of growth, were significantly
different compared to both untreated cells and PPP3.7 not containing paclitaxel. This

Figure 17. Therapeutic activity of electrospun fibers and controls on VSMCs treated for 3
days. ****=p<0.0001 and *=p<0.05 both compared to untreated VSMCs, #=p<0.05
compared to PPP3.7. The paclitaxel alone group contained 0.3 µg/mL paclitaxel.
Mean ± SEM.
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indicates that the drug was able to maintain therapeutic activity throughout the
electrospinning process.
It is noted that there is still a slight inhibitory effect on the growth of VSMCs by
electrospun fibers not containing paclitaxel. There are two possible explanations for this
to occur. First, the fibers were placed directly into the wells on top of the cell layer which
could cause cell death. This could be avoided in future studies by either conditioning the
media with the fiber treatments or by using transwell inserts to prevent the fibers from
physically disturbing the cells. Secondly, the sterilization process for the fibers may not
have been sufficient enough to prevent contamination of the cells also leading to cell
death.
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CHAPTER 5: CONCLUSION
The goal of this project was to determine the feasibility of incorporating paclitaxel
into electrospun fibers containing PgP3.7 to be used as vascular sutures than can locally
inhibit the proliferation of VSMCs and ultimately prevent intimal hyperplasia and
stenosis following anastomosis procedures. The first aim to successfully fabricate and
characterize the electrospun fibers containing both PgP and paclitaxel was met and
confirmed by fiber imaging and mechanical testing which showed uniform fiber
formation with minimal defects and consistent ductile mechanical properties for each
electrospun fiber type. However, the mechanical strength of the electrospun fibers was
nearly twenty times lower than commercially available sutures.
The second aim of this project was to determine the loading efficiency and release
kinetics of the paclitaxel-loaded electrospun fibers. The hypothesis was confirmed that
electrospun fibers containing PgP3.7 were able to load significantly more paclitaxel with
greater loading efficiency compared to those without due to the large hydrophobic region
of the PgP3.7 binding to the hydrophobic drug. Congruently, the release profiles of both
PgP3.7 and non-PgP3.7 paclitaxel loaded electrospun fibers demonstrated a slow and
sustained release profile with slightly more drug released over time from PgP3.7
containing fibers.
The third and final aim of this project was to ensure that the therapeutic activity of
paclitaxel was not compromised during the electrospinning process. This was done invitro by culturing primary VSMCs and treating them for three days with electrospun
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fibers containing paclitaxel and comparing the growth inhibitory effects to untreated
cells, non-drug-loaded electrospun fibers and paclitaxel alone. The results showed that
paclitaxel loaded fibers had significantly more inhibitory effects when compared to
untreated cells.
In conclusion, all three aims of this study were met and the results were very
promising for the potential use of paclitaxel loaded electrospun fibers as sutures to
prevent intimal hyperplasia following vascular anastomosis.
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CHAPTER 6: LIMITATIONS AND FUTURE STUDIES
Moving forward with this project, it is important to consider the overall goal
which is to develop a dual-drug-eluting vascular suture to combat both thrombosis and
stenosis following an anastomosis procedure. Previously in the 4D lab, the fabrication
and characterization of electrospun heparin-immobilized sutures was successfully
completed to address the issue of thrombosis and also to assist in inhibition of VSMC
proliferation. In the future, steps should be taken to combine both paclitaxel incorporated
electrospun fibers and heparin-immobilization and test the potential sutures in-vivo with a
rat vein anastomosis model.
One of the major limitations of this project is the mechanical strength of the
electrospun fibers compared to commercially available vascular sutures. There are
several potential solutions that can be explored. The first would be to attempt the coresheath method of electrospinning where the paclitaxel and PgP3.7 incorporated polymer
mixture could surround a more mechanically robust polymeric core such as
polycaprolactone (PCL) or poly-L-lactic acid (PLLA) similar to the study done by
Padmakumar et. al. [21] This method would still allow for the slow and sustained release
of paclitaxel and the surface exposure of PgP3.7 for heparin immobilization since the
biological drug heparin cannot be subjected to the volatile solvent and high voltage
during electrospinning, but may provide additional mechanical support by the core.
Another option to pursue would be another more traditional fabrication technique such as
melt extrusion where both drugs could be incorporated directly into the fiber, but the
monofilament structure would increase the mechanical strength.
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